homoarginine | 156-86-5

• 物质功能分类: 生物化工 - 常见氨基酸及蛋白质类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: homoarginine
• 英文别名: N⁶-carbamimidoyl-DL-lysine；N⁶-Carbamimidoyl-DL-lysin；N⁶-Carbamimidoyl-lysin；2-amino-6-guanidinohexanoic acid；2-amino-6-guanidohexanoic acid；Homoarginin；L-(+)-Homoarginine hydrochloride；2-amino-6-(diaminomethylideneamino)hexanoic acid
• CAS: 156-86-5
• 化学式: C₇H₁₆N₄O₂
• mdl: MFCD18430846
• 分子量: 188.23
• InChiKey: QUOGESRFPZDMMT-UHFFFAOYSA-N

物化性质

• 熔点：
  207-209 °C
• 沸点：
  376.3±52.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  -3.7
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  4

安全信息

• 安全说明：
  S36,S36/37/39,S60,S61
• 危险品运输编号：
  UN 3077 9/PG 3
• WGK Germany：
  3
• 海关编码：
  29152900
• 危险品标志：
  Xn,Xi,N
• RTECS号：
  AG3500000
• 危险类别码：
  R22,R36/37/38,R50/53
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  Store at room temperature.

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Homoarginine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Homoarginine
CAS number: 156-86-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H16N4O2
Molecular weight: 188.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

H-HoArg-OH（L-同型精氨酸）是一种器官特异性、无竞争性的血清“骨和肝”碱性磷酸酶抑制剂。

靶点

Target	Value
碱性磷酸酶

体外研究

研究表明，H-HoArg-OH（L-同型精氨酸）作为一种与精氨酸相似的氨基酸，是人类骨和肝碱性磷酸酶的强大抑制剂，而对肠和胎盘碱性磷酸酶几乎没有影响。与此不同的是，另一种化合物H-HoArg-OH能够抑制肠和胎盘碱性磷酸酶但不抑制肝脏和骨骼中的酶。这四种组织是血清碱性磷酸酶的主要来源。此外，内源性氨基酸H-HoArg-OH的低水平与心血管疾病有关。

反应信息

• 作为反应物：
  描述：

  homoarginine 在 盐酸 作用下， 生成 N²-benzoyl-N⁶-carbamimidoyl-DL-lysine amide; hydrochloride
  参考文献：
  名称：

  Kitagawa; Izumiya, Journal of Biochemistry, 1959, vol. 46, p. 1159,1161

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 phosphonium iodide 、 氢碘酸 作用下， 生成 homoarginine
  参考文献：
  名称：

  Steib, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1926, vol. 155, p. 298

  摘要：

  DOI：

文献信息

• Small molecules for treatment of hypercholesterolemia and related diseases
  申请人：Sircar C. Jagadish

  公开号：US20050277690A1

  公开（公告）日：2005-12-15

  The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases.

  本发明提供了适用于增强哺乳动物体内逆向胆固醇转运的组合物。这些组合物适合口服给药，并可用于治疗和/或预防高胆固醇血症、动脉粥样硬化及相关心血管疾病。
• [EN] INDOLESULFONYL PROTECTING GROUPS FOR PROTECTION OF GUANIDINO AND AMINO GROUPS<br/>[FR] GROUPES PROTECTEURS À BASE D'INDOLE SULFONYLE POUR LA PROTECTION DE GROUPES GUANIDINE ET AMINO
  申请人：LONZA AG

  公开号：WO2009135645A1

  公开（公告）日：2009-11-12

  The invention relates to indolesulfonyl halogenides which are useful for the protection of organic compounds comprising at least one guanidino moiety and/or at least one amino group. The invention further relates to a process for their preparation and their use as protecting reagents. The invention also relates to the process for the protecting reaction and to the protected compounds thereof.

  这项发明涉及对至少含有一个胍基团和/或至少含有一个氨基团的有机化合物进行保护的吲哚磺酰卤化物。该发明还涉及它们的制备过程以及它们作为保护试剂的用途。该发明还涉及保护反应的过程以及所保护化合物。
• [EN] NOVEL HEPCIDIN MIMETICS AND USES THEREOF<br/>[FR] NOUVEAUX MIMÉTIQUES D'HEPCIDINE ET LEURS UTILISATIONS
  申请人：BAYER HEALTHCARE LLC

  公开号：WO2018128828A1

  公开（公告）日：2018-07-12

  The present invention relates to novel peptides acting as hepcidin mimetics, as well as analogues and derivatives thereof. The invention further relates to compositions comprising the peptides of the present invention, and to the use of the peptides in the prophylaxis and treatment of hepcidin-associated disorders, including prophylaxis and treatment of iron overload diseases such as hemochromatosis, iron-loading anemias such as thalassemia, and diseases being associated with ineffective or augmented erythropoiesis, as well as further related conditions and disorders described herein.

  本发明涉及作为赫普西定类似物的新型肽，以及其类似物和衍生物。该发明还涉及包含本发明肽的组合物，以及在预防和治疗赫普西定相关疾病中使用这些肽，包括预防和治疗铁过载疾病如血色病、铁负荷性贫血如地中海贫血，以及与效率低下或增强的红细胞生成相关的疾病，以及本文所述的进一步相关病症和疾病。
• [EN] ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2020229982A1

  公开（公告）日：2020-11-19

  The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in a subject in need thereof. Formula (I):

  本公开提供包含STING调节剂的抗体药物结合物。还提供了包含该抗体药物结合物的组合物。这些化合物和组合物对于刺激需要免疫反应的受试者是有用的。公式（I）:
• N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
  申请人：——

  公开号：US20030092698A1

  公开（公告）日：2003-05-15

  This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

  这项发明涉及N-酰基吡咯啉-2-基烷基苯甲酰胺衍生物，用于通过将这些衍生物与含有凝血因子Xa的组合物接触来抑制凝血因子Xa的活性。本发明还涉及含有这些衍生物的组合物、它们的制备方法，以及它们的用途，例如用于抑制凝血酶的形成或用于治疗患有与生理上有害的凝血酶过量相关的疾病状态的患者。